U.S. Adults With Diabetes Take Control of Care Through Innovative Use of Digital Resources

Manhattan ResearchMore than ever, type 1 and type 2 diabetes patients are turning to online channels to research treatment and product information, to seek advice and support from others, and to manage their condition. According to pharmaceutical and healthcare market research company Manhattan Research's Cybercitizen Health™ study, nine out of ten online diabetes patients use the Internet to research health information, and two-thirds use the Internet to access pharmaceutical product information.

More so than other therapeutic categories, diabetes patients have an extremely active blog community. Celebrity diabetes patients have also gotten involved in the online mix - singer Nick Jonas teamed up with Bayer Healthcare to launch NickSimpleWins.com, a diabetes awareness site featuring a blog, online videos, and links to songs from The Jonas Brothers.

A few diabetes product websites have been particularly successful in serving the needs of consumers online over the past year. According to Manhattan Research's ePharma Consumer® study, Sanofi-Aventis' Lantus.com is the highest-rated site in terms of visitor satisfaction, out of a pool of more than 200 product websites. Consumers applaud the site's "very informative, interactive instruction guides" and appreciate that "all medical information is thoroughly disclosed." Consumers also rated Merck's Januvia.com as one of the top pharmaceutical product brand sites for visitor satisfaction.

Request a Complimentary Overview of Online Diabetes Market
Manhattan Research offers a complimentary overview of how diabetes patients use the Internet and other technology for healthcare. This one-page snapshot is a preview of the Diabetes Segmentation Module, which is a comprehensive analysis of the diabetes patient market based on Cybercitizen Health™ and ePharma Consumer®. To request your complimentary snapshot of the diabetes market or any of the other 100+ consumer therapeutic groups we cover, please visit www.manhattanresearch.com/products/Therapeutic_Segmentations/therapeutic-segmentation-overview-request.aspx

Consumer and Physician Segmentation Modules
Manhattan Research provides comprehensive analyses of over 125+ consumer therapeutic and physician specialist groups. Each Segmentation Module is an in-depth view of a particular market’s adoption and use of the Internet and other technology for healthcare, treatment, and product decisions and focuses heavily on tactical execution. The segmentation modules provide clients with the necessary market data and insights to make better informed decisions during brand planning and to connect with a particular disease class or specialist group through digital strategies.

Consumer therapeutic module topics include media consumption across traditional and alternative resource channels, website usage metrics, connectivity and interaction with physicians, health site engagement, use of branded and unbranded product sites, Web 2.0, interest in online health services and tools, DTC advertising, actions taken offline after health info seeking, and drivers to requesting a prescription drug.

Physician specialist module topics include interactive detailing, Web 2.0, pharmaceutical customer service portals, tech-enabled sales reps, search engines, online and offline professional information sources, email use and opportunity, patient interaction and education, digital health infrastructure, and mobile technology profile.

For a list of available consumer therapeutic segmentation modules and topics, please visit www.manhattanresearch.com/products/Therapeutic_Segmentations

For a list of available physician specialist segmentation modules and topics, please visit www.manhattanresearch.com/products/Specialist_Segmentations

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm. We conduct annual research studies covering eHealth trends among physicians and consumers, including Taking the Pulse®, Taking the Pulse® Europe, Taking the Pulse® Asia, Cybercitizen Health™, Cybercitizen Health™ Europe, ePharma Consumer®, and ePharma Physician®. Broad consumer and physician research is complemented by targeted analysis among more than 100 consumer therapeutic segments and 25 physician specialist segments. For information, please visit www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

Most Popular Now

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

Pfizer invests $43 billion to battle cancer

Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Scientists reveal a potential new approach to trea…

Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead ...

Normalizing tumor blood vessels may improve immuno…

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited e...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...